NovaGenesis Peptide Research
← Peptide Library
METABOLIC RESEARCHRTA

Retatrutide

A multi-receptor research peptide studied for metabolic signalling, energy regulation, and hormonal interaction across long-duration research models.

Half-Life
Long
Onset
Gradual
Symbol
RTA
Category
Metabolic

⏱ Half-Life

Long duration profile

Retatrutide demonstrates a long half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.

⚡ Onset Characteristics

Gradual measurable response

Onset is observed as gradual — a property that influences how researchers structure comparative studies versus other compounds in the metabolic research category.

🧠 Key Notes

What makes it distinct

  • 01High research interest in 2025–2026
  • 02Multi-target receptor interaction profile
  • 03Suitable for long-duration observational studies

🧬 Mechanism of Action

How it works

Retatrutide is a synthetic triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors. GLP-1 activation enhances glucose-dependent insulin release and slows gastric emptying, GIP activation amplifies post-prandial insulin response and modulates adipose lipid handling, and glucagon receptor activation increases basal energy expenditure and hepatic lipid oxidation. The combined signalling produces broader metabolic effects than mono- or dual-agonists like semaglutide or tirzepatide, addressing both intake (appetite, satiety) and output (energy expenditure) sides of the energy balance equation.

✨ Documented Benefits

What the research shows it supports

B01Substantial reductions in body weight and visceral adiposity in Phase II trials — among the largest effect sizes recorded for a metabolic peptide.
B02Improved glycaemic control and insulin sensitivity in research populations with insulin resistance.
B03Increased basal energy expenditure via glucagon-receptor activation, distinguishing it from GLP-1-only agonists.
B04Once-weekly dosing schedules in published protocols, simplifying long-duration study design.

🔍 Research Insights

What the literature shows

INSIGHT 01

Acts simultaneously on GLP-1, GIP, and glucagon receptors — a triple-agonist profile that distinguishes it from earlier mono- or dual-agonist peptides.

INSIGHT 02

Long half-life supports once-weekly dosing models in published trials, simplifying compliance variables in study design.

INSIGHT 03

Phase II data has shown some of the largest weight-reduction effect sizes recorded in metabolic peptide literature to date.

🧪 Typical Research Use Cases

Where it appears in study design

USE CASE 01

Comparative metabolic studies versus tirzepatide and semaglutide.

USE CASE 02

Long-duration energy expenditure and adipose modelling.

USE CASE 03

Glucose homeostasis research in insulin-resistant models.

📚 References

Peer-reviewed literature

Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.

  1. [01]

    Jastreboff, A. M. et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526.

    New England Journal of Medicine ↗
  2. [02]

    Rosenstock, J. et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet, 402(10401), 529–544.

    The Lancet ↗
  3. [03]

    Sanyal, A. J. et al. (2024). Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction–Associated Steatotic Liver Disease. Nature Medicine, 30, 2037–2048.

    Nature Medicine ↗
  4. [04]

    Coskun, T. et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247.

    Cell Metabolism ↗

Continue Exploring

Also explore: MOTS-c, Semax, GHK-Cu

MOTS-c →Semax →GHK-Cu →Half-Life Guide →Metabolic Research →